SG Americas Securities
TCRR

SG Americas Securities’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

SG Americas Securities’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-22,569
Closed -$105K – 3603
2021
Q4 		$105K Sell
22,569
-3,517
-13% -$22K ﹤0.01% 3065
2021
Q3 		$222K Buy
26,086
+11,710
+81% +$165K ﹤0.01% 3166
2021
Q2 		$236K Buy
14,376
+4,263
+42% +$86.1K ﹤0.01% 2267
2021
Q1 		$223K Buy
10,113
+6,560
+185% +$179K ﹤0.01% 2607
2020
Q4 		$110K Buy
+3,553
New +$89.8K ﹤0.01% 2991
2020
Q3 		– Sell
-8,910
Closed -$137K – 3666
2020
Q2 		$137K Buy
+8,910
New +$103K ﹤0.01% 3150

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

SG Americas Securities's TCRR Position: Q1 2022 in Review

SG Americas Securities sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2022, closing a stake of 22,569 shares — an estimated $105K sold.

SG Americas Securities first reported a position in TCRR in Q2 2020 and held it in 6 quarters. The position peaked at $236K in Q2 2021. 94 funds tracked by Wall St. Rank hold TCRR as of Q1 2022.

  • SG Americas Securities reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • SG Americas Securities sold 22,569 TCR2 Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $105K.
  • SG Americas Securities first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2020 and held it in 6 quarters.
  • SG Americas Securities's TCR2 Therapeutics Inc. Common Stock position peaked at $236K in Q2 2021.
  • 94 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2022.

Based on SG Americas Securities's 13F filing for Q1 2022, filed 29 Apr 2022.